期刊文献+

维甘乳膏联合维生素B_6治疗卡培他滨相关手足综合征的临床观察 被引量:2

Clinical Observation of Weigan Cream Combined with Vitamin B_6 in the Treatment of Capecitabine Related Hand Foot Syndrome
原文传递
导出
摘要 目的:观察维甘乳膏联合维生素B6治疗卡培他滨相关手足综合征的疗效与安全性。方法:选择56例结、直肠癌或胃癌患者,均采用卡培他滨为主的化疗方案治疗,所有患者在化疗过程中共出现手足综合征105次(同一患者可重复出现),按照症状出现次数随机分为治疗组(53次)与对照组(52次)。对照组患者仅口服维生素B630 mg,tid;治疗组患者在对照组基础上外用维甘乳膏涂抹于局部,一日4次。两组患者均用药至恢复正常。观察比较患者手足综合征毒性等级以及治疗过程中的不良反应发生情况。结果:卡培他滨相关手足综合征的发生例数在不同年龄、性别和肿瘤类型间的差异无统计学意义(P>0.05)。治疗组总有效率(88.7%)显著高于对照组(63.5%),两组比较差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:维甘乳膏联合维生素B6治疗卡培他滨相关手足综合征疗效和安全性均较好,可以提高患者对化疗的耐受性。 OBJECTIVE: To observe therapeutic efficacy of Weigan cream combined with vitamin B6 in the treatment of capecitabine related hand foot syndrome (HFS). METHODS: 56 patients who had been diagnosed by pathological or cytological of colorectal cancer or gastric cancer were treated by capecitabine, while 105 times HFS happened (same patient may suffered from the symptoms repeatedly). Those patients were randomly divided into treatment group (53 times) and control group (52 times) according to the number of symptom occurrence. Control group was given vitamin B,, orally '30 mg, 3 times a day; treatment group was additionally given Weigan Cream for local use 4 times a day on the basis of control group. 2 groups returned to normal after treatment. Whether HFS toxicity was downgraded were compared and ADR were also observed during treatment. RESULTS:There was no statistical significance in the case number of capecitabine related HFS in different age, gender and tumer type groups (P〉 0.05). The total effective rate of treatment group(88.7% ) was higher than that of control group( 63.5%); there was statistical significance (P〈0.05). The incidence of ADR in 2 groups had no statistical significance(P〉0.05). CONCLUSIONS: Weigan Cream combined with vitamin B6 has ideal treatment effect on hand foot syndrome caused by capecitabine, and improve patients' tolerance to chemotherapy.
出处 《中国药房》 CAS CSCD 2013年第48期4529-4531,共3页 China Pharmacy
基金 国家自然科学基金资助项目(No.81272556) 广东省科学事业费专项项目(No.2010B060900016)
关键词 维甘乳膏 维生素B6 化疗 手足综合征 卡培他滨 Weigan cream Vitamin B6 Chemotherapy Hand foot syndrome Capetitabine
  • 相关文献

参考文献9

二级参考文献23

  • 1李珊瑚,李勇敏,彭淑珍.康复新液对家兔创伤愈合的影响[J].临床和实验医学杂志,2006,5(6):730-731. 被引量:65
  • 2王亚伟.对胃癌诊断研究与分析和康复新液、瑞波特片对胃癌细胞的生长抑制凋亡的研究[J].中华临床医学卫生杂志,2006,4(8):33-35. 被引量:9
  • 3Kim JG,Sohn SK,Chae YS,et al. Muhicenter phase Ⅱ study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group[J ] .Br J Cancer, 2008, 98 (3) :542.
  • 4Kang Y, Kang WK, Shin DB,et al. Randomized phase Ⅲ trial of capecitabine/ cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first- line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results[J ] .Proc Am Soc Clin Oncol , 2006,24(18) : 4 018.
  • 5Cunningham MD, Rao S, Starling N,et al. Randomised multicentre phase Ⅲ study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer. The RE- AL 2 trial[J ]. Proc Am Soc Clin Oncol, 2006, 24(18) : 4 017.
  • 6Thuss- Patience PC, Kretzschmar A, Dogan Y, et al. Capecitabine and docetaxel for advanced gastric cancer [J ] .J Clin Oncol, 2006,24(18): 4 068.
  • 7Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecit- abine-induced hand-foot syndrome and antitumor activity[J]. Oncology( Huntingt), 2002,16 ( 12 Suppl No 14) : 31 37.
  • 8Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase 11 study of capecitabine in paelitaxel refractory metastatic breast caneer[J]. J Clin Onco1,1999,17(3) :485-493.
  • 9Walko CM, Lindley C. Capecitabine: a review[J]. Clin Ther, 2005,27(1) :23-44.
  • 10Lin EH, Curley SA, Crane CC, et al. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: po- tential benefits and COX-2 as the common mediator in pain, toxicities and survival[J]. Am J Clin Oncol,2006,29 232-239.

共引文献41

同被引文献21

  • 1Yuen M F,Hou J L,Chutaputti A.Hepatocellular carcinoma in the Asia–Pacific region[J].Gastroenterol Hepatol,2009,24:346.
  • 2Chunping Wang,Yinting Lu,Hong Wang,et al.Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma[J].Experimental and Therapeutic Medicine,2012,4(10):188.
  • 3Hagemann I,Proksch E.Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis[J].Acta Derm Venereo,1996,176:353.
  • 4Trotti A,Colevas A D,Setser A,et al.CTCAE v3.0:development of a comprehensive grading system for the adverse effects of cancer treatment[J].Semin Radiat Oncol,2003,13:176.
  • 5Bruix J,Sherman M.Management of hepatocellular carcinoma Practice Guidelines Committee,American Association for the Study of Liver Diseases[J].Hepatology,2005,42:1208.
  • 6Therasse P,Arbuck S G,Eisenhauer E A,et al.New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada[J].J Natl Cancer Inst,2000,92:205.
  • 7Dranitsaris G,Vincent M D,Yu J,et al.Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib[J].Ann Oncol,2012,23:2103.
  • 8Manchen E,Robert C,Porta C.Management of tyrosine kinase inhibitor-induced handfoot skin reaction:viewpoints from the medical oncologist,dermatologist,and oncology nurse[J].J Support Oncol,2011,9:13.
  • 9Cheng A L,Kang Y K,Chen Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised,doubleblind,placebo-controlled trial[J].Lancet Oncol,2009,10:25.
  • 10安林静,郝丽燕,张昕,张丽娜,李因茵,陆荫英,王春平,曲建慧,杨永平.索拉非尼治疗肝细胞癌患者的不良反应及其对预后的影响[J].解放军护理杂志,2011,28(17):8-11. 被引量:6

引证文献2

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部